drugset / Trial / NCT04582955
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined with chemotherapy for stage II - III triple-negative breast cancer，and to compare the efficacy and safety of chemotherapy with Chidamide and chemotherapy alone in the neoadjuvant treatment of stage II - III triple-negative breast cancer
Timeline
- Start
- 2020-10-30
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |